Thank you for subscribing!
Finfeed Archived Nov 13, 2018
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.
Next Investors Archived Nov 13, 2018
Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.
Finfeed Archived Nov 01, 2018
Race Oncology (ASX:RAC) has come to agreement with Biosynergy to pursue licensing deals for chemotherapy drug, Bisantrene.
Next Investors Archived Oct 30, 2018
Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.
Get expert stock analysis direct in your inbox
Finfeed Archived Oct 29, 2018
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.
Finfeed Archived Oct 17, 2018
The biotech sector was yesterday led by biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) which ended the day 217% higher.
Finfeed Archived Oct 03, 2018
There are few companies dealing in nanotechnology in Australia, fewer still in the biotech space, which could make this a unique investment sector if investors are so inclined.
Finfeed Archived Sep 07, 2018
The ethics of big pharma are debatable and deserve a long-form serious analysis, so let’s avoid the debate for now and look at the good work small biotech companies are doing.
Finfeed Archived Sep 03, 2018
Prescient Therapeutics Ltd (ASX:PTX) has today advised it has identified an improved manufacturing route for PTX-100 for use in its upcoming pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial.
The importance of biotech shouldn’t be underestimated, considering it can lead to tailor-made cures, eradication of diseases, better diagnostics and an overall healthier society.
Finfeed Archived Aug 30, 2018
Clinical-stage oncology company, Prescient Therapeutics (ASX:PTX), this morning updated the market on its trial of PTX-200 with cytarabine in relapsed or refractory acute myeloid leukaemia (AML).
Finfeed Archived Jul 26, 2018
Prescient Therapeutics Ltd (ASX:PTX) has received a Notice of Allowance for a new patent covering its lead clinical compound PTX-200 for the treatment of ovarian cancer in the United States.
Finfeed Archived Jul 19, 2018
When Rhythm Biosciences (ASX:RHY) listed on the ASX in December 2017 its slogan was ‘taking Australian innovation to the world’ - its delivered in spades.
Finfeed Archived Jun 15, 2018
Medical diagnostics small cap Rhythm Biosciences Limited (ASX:RHY) has today announced that its new shareholder Merchant Group has increased its equity stake in the company from 5.02% to 7.01%.
Finfeed Archived Jun 12, 2018
Medical diagnostics innovator, Rhythm Biosciences (ASX:RHY), has welcomed leading biotech investor, Merchant Group, as a major new shareholder.
Finfeed Archived May 23, 2018
Bionomics Limited (ASX:BNO) has today announced that a Phase 2 clinical trial for BNC210 has commenced in elderly patients with agitation in a hospital setting.
Finfeed Archived May 22, 2018
Rhythm Biosciences Limited (ASX:RHY) has strengthened its management team by appointing two experienced health sector executives, including Glenn Gilbert as Chief Operating Officer.
Finfeed Archived May 21, 2018
BARD1 Life Sciences (ASX:BD1) has penned an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test using ProcartaPlex® technology.
Join Our Mailing List
